Infineon Expands Infringement Lawsuit Against Innoscience
By Pierre Bertrand
Infineon Technologies said it expanded its infringement lawsuit against Innoscience, adding claims against the company and affiliates for alleged infringement of three additional patents.
The expansion comes after the German chip maker in March launched a legal challenge against U.S. semiconductor company Innoscience in California relating to gallium nitride technology for the production of semiconductors.
The three additional patents also relate to gallium nitride technology owned by Infineon, the company said.
In addition, it lodged a complaint with the U.S. International Trade Commission containing what Infineon said were legal claims referring to the same four patents covered by the lawsuit.
Infineon is seeking a permanent injunction for the infringement of its U.S. patents.
Innoscience wasn't immediately available for comment. Last month, the company denied Infineon's infringement allegations and questioned the validity of its patents.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
July 26, 2024 11:36 ET (15:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks